Age Disparity in the Dissemination of Imatinib for Treating Chronic Myeloid Leukemia

Permutation tests for joinpoint regression with applications to cancer rates

Hyune-Ju Kim, Michael P. Fay, Eric J. Feuer et al. · Statistics in Medicine · 2000 · 6.1K citations

Public Health, Biostatistics, Epidemiologic Methods +12

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Brian Druker, Moshe Talpaz, Debra Resta et al. · New England Journal of Medicine · 2001 · 5.2K citations · Full text

Medicine, Oncology, Pharmacology +12

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Brian Druker, Shu Tamura, Elisabeth Buchdunger et al. · Nature Medicine · 1996 · 3.7K citations

Life Sciences, Molecular Biology, Oncology +13

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Brian Druker, François Guilhot, Stephen G. O’Brien et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

Medicine, Hematology, Oncology +13

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

Brian Druker, Charles L. Sawyers, Hagop M. Kantarjian et al. · New England Journal of Medicine · 2001 · 2.7K citations · Full text

Medicine, Hematology, Oncology +17